by Charles Bankhead The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers. The action represents the first tumor-agnostic approval for an antibody-drug conjugate targeting HER2-positive tumors. According … Read more The post Enhertu Gets Tumor-Agnostic FDA Approval for HER2-Positive Cancers <br> <p>— About half of patients responded, duration of response as long as 19 months in three trials</p> appeared first on Clearity Foundation ..read more

Clearity’s Perspective: This article highlights the importance of learning ways to cope with and manage stress after an ovarian cancer diagnosis. The study, performed only on mice, suggests that there may be a link between overproduction of stress hormones and … Read more The post Stress-Induced Immune Changes May Help Cancer Spread appeared first on Clearity Foundation ..read more

By Heidi Splete Many women with cancer want advice for managing sexual function issues, and clinicians are tuning in, new studies suggest. Decreased sexual function is a side effect of many types of cancer, notably uterine, cervical, ovarian, and breast … Read more The post Women’s Cancers: Clinicians Research, Advise on Sexual Dysfunction appeared first on Clearity Foundation ..read more

By Ryan Scott Patients who are heavily pretreated with recurrent low-grade serous ovarian cancer (LGSOC) had high response rates, regardless of the number of prior lines of therapy received, when treated with avutometinib (previously VS-6766) plus defactinib, according to data … Read more The post Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC appeared first on Clearity Foundation ..read more

Clearity’s Perspective: At the SGO meeting several presentations described how circulating tumor DNA (ctDNA) may be a new, personalized, sensitive tool to help evaluate treatment de-escalation, monitor minimal residual disease (MRD), and track treatment response in ovarian cancer. The application … Read more The post ctDNA Offers Potential Biomarker for PARP Inhibitor Maintenance Therapy in Epithelial Ovarian Cancer appeared first on Clearity Foundation ..read more

By Kristi Rosa Rezatapopt (PC14586) elicited responses with a favorable toxicity profile in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations, according to data from the phase 1/2 PYNNACLE study (NCT04585750) presented at the 2024 SGO Annual … Read more The post Rezatapopt Shows Preliminary Efficacy in TP53 Y220C–Mutated Advanced Ovarian Cancer appeared first on Clearity Foundation ..read more

Clearity’s Perspective: Previous research in different types of cancer has suggested that there is a relationship between a cancer patient’s gut microbiota (microorganisms that live in the digestive tract) composition and the response to immune checkpoint inhibitor therapy; however, … Read more The post New microbiome insights could help boost immunotherapy for a range of rare cancers appeared first on Clearity Foundation ..read more

By Mike Basset Risk management strategies including bilateral salpingo-oophorectomy (BSO) for ovarian cancer and MRI surveillance for breast cancer were associated with a significant reduction in mortality for women with BRCA1/2 sequence variations, according to results from two cohort studies … Read more The post Cancer Prevention Strategies Linked to Mortality Reduction in BRCA Carriers appeared first on Clearity Foundation ..read more

Clearity’s Perspective: Clearity offers emotional support to people with ovarian cancer and their caregivers through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team … Read more The post Study Shows Disparities in Psychosocial Outcomes Among Women With Ovarian Cancer in Rural vs Urban Areas appeared first on Clearity Foundation ..read more

By Mark Fuerst About half of patients with platinum-sensitive relapsed ovarian cancer (PSROC) on maintenance poly (ADP-ribose) polymerase inhibitor (PARPi) therapy who showed RECIST progression did not have cancer antigen-125 (CA-125) progression, challenging current guidelines, according to a new study.… Read more The post Ursula Matulonis, MD, on Concordance of CA-125 and Radiographic Progression in Ovarian Cancer appeared first on Clearity Foundation ..read more